Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.34 |
| ▸ | FABP4 | P15090 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2155244 | 0.79 | MEN1 (0.43) | HPGDTSHRMEN1KMT2A | |
| SCHEMBL2156098 | 0.76 | CYP19A1 (0.39) | TSHRMEN1KMT2A | |
| SCHEMBL4622838 | 0.71 | SIRT2 (0.35) | SIRT2KMT2A | |
| SCHEMBL4622835 | 0.71 | SIRT2 (0.35) | SIRT2KMT2A | |
| SCHEMBL2155852 | 0.68 | CYP19A1 (0.43) | HPGDMEN1KMT2A | |
| SCHEMBL2155276 | 0.67 | MAPT (0.40) | HPGDTSHRMEN1KMT2A | |
| SCHEMBL2155246 | 0.64 | TSHR (0.39) | NPSR1HPGDTSHR | |
| SCHEMBL14883877 | 0.62 | SIRT2 (0.45) | SIRT2 | |
| SCHEMBL4968297 | 0.60 | KMO (0.52) | TSHRMEN1KMT2A | |
| SCHEMBL8793611 | 0.59 | AKR1B1 (0.38) | HPGDTSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080161352-A1 | Substituted Benzo-Condensed Cycloheptanone Derivatives and the Use Thereof for Medicament Production | GRUENENTHAL GMBH (DE) | 2008-07-03 | — | — | US | claimed |
| US-7973072-B2 | Pain, eating disorders, neurodegenerative disorders, memory impairment; attention deficit syndrome, opioid tolerance, drug addiction; (4-oxothiochroman-3,3-diyl)bis(methylene)bis(3-(trifluoromethyl)benzoate for example | GRUENENTHAL GMBH (DE) | 2011-07-05 | — | — | US | disclosed |
| US-20080161352-A1 | Substituted Benzo-Condensed Cycloheptanone Derivatives and the Use Thereof for Medicament Production | GRUENENTHAL GMBH (DE) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161352-A1 | Substituted Benzo-Condensed Cycloheptanone Derivatives and the Use Thereof for Medicament Production | BCKDK, SYMPK, DHPS | SIRT2 1043/4885FABP4 2297/4885NPSR1 2327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.